A common polymorphism in SCN5A is associated with lone atrial fibrillation

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 35-41

  Chen, L Y ^a   Ballew, J D ^a   Herron, K J ^a   Rodeheffer, R J ^a   Olson, T M ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL TYPE V ALPHA;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG TARGETING; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HUMAN; HYPOTHESIS; LONE ATRIAL FIBRILLATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SCN5A GENE; SEQUENCE ANALYSIS;

ATRIAL FIBRILLATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SODIUM CHANNELS;

EID: 33845983622     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100016     Document Type: Article

References (38)

1. Thom, T. et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, e85-e151 (2006).
2. Krahn, A.D., Manfreda, J., Tate, R.B., Mathewson, F.A. & Cuddy, T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98, 476-484 (1995).
3. Benjamin, E.J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840-844 (1994).
4. Psaty, B.M. et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96, 2455-2461 (1997).
5. Chugh, S.S., Blackshear, J.L., Shen, W.K., Hammill, S.C. & Gersh, B.J. Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll. Cardiol. 37, 371-378 (2001).
6. Brugada, R. et al. Identification of a genetic locus for familial atrial fibrillation. N. Engl. J. Med. 336, 905-911 (1997).
7. Darbar, D. et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J. Am. Coll. Cardiol. 41, 2185-2192 (2003).
8. Ellinor, P.T., Shin, J.T., Moore, R.K., Yoerger, D.M. & MacRae, C.A. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 107, 2880-2883 (2003).
9. Chen, Y.H. et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251-254 (2003).
10. Yang, Y. et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet. 75, 899-905 (2004).
11. Xia, M. et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem. Biophy. Res. Commun. 332, 1012-1019 (2005).
12. Olson, T.M. et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 15, 2185-2191 (2006).
13. Lai, L.P. et al. Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. Am. Heart J. 144, 485-490 (2002).
14. Schreieck, J. et al. C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation. Am. Heart J. 148, 545-550 (2004).
15. Tsai, C.T. et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 109, 1640-1646 (2004).
16. Ravn, L.S. et al. Relation of 97T polymorphism in KCNE5 to risk of atrial fibrillation. Am. J. Cardiol. 96, 405-407 (2005).
17. Fox, C.S. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 291, 2851-2855 (2004).
18. Arnar, D.O. et al. Familial aggregation of atrial fibrillation in Iceland. Eur. Heart J. 27, 708-712 (2006).
19. Wang, Q. et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805-811 (1995).
20. Chen, Q. et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296 (1998).
21. Akai, J. et al. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 479, 29-34 (2000).
22. Schott, J.J. et al. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet. 23, 20-21 (1999).
23. Benson, D.W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112, 1019-1028 (2003).
24. Splawski, I. et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297, 1333-1336 (2002).
25. Olson, T.M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293, 447-454 (2005).
26. Ackerman, M.J. et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 1, 600-607 (2004).
27. Makielski, J.C. et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ. Res. 93, 821-828 (2003).
28. Viswanathan, P.C., Benson, D.W. & Balser, J.R. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J. Clin. Invest. 111, 341-346 (2003).
29. Ye, B., Valdivia, C.R., Ackerman, M.J. & Makielski, J.C. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol. Genomics 12, 187-193 (2003).
30. Morita, H. et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J. Am. Coll. Cardiol. 40, 1437-1444 (2002).
31. Zhang, L. et al. An intronic mutation causes long QT syndrome. J. Am. Coll. Cardiol. 44, 1283-1291 (2004).
32. Bezzina, C.R. et al. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 113, 338-344 (2006).
33. Chen, J.-Z. et al. Single nucleotide polymorphisms of the SCN5A gene in Han Chinese and their relation with Brugada syndrome. Chin. Med. J. 117, 652-656 (2004).
34. Allessie, M.A., Bonke, F.I. & Schopman, F.J. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ. Res. 41, 9-18 (1977).
35. Roden, D.M. Mechanisms and management of proarrhythmia. Am. J. Cardiol. 82, 49I-57I (1998).
36. Brugada, R. et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101, 510-515 (2000).
37. Fuster, V. et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104, 2118-2150 (2001).
38. Redfield, M.M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289, 194-202 (2003).